248 related articles for article (PubMed ID: 16236891)
41. [Respiratory evolution of patient with mucoviscidosis treated with mucolytic agents plus dornase alfa].
Derelle J; Bertolo-Houriez E; Marchal F; Weber M; Virion JM; Vidailhet M
Arch Pediatr; 1998 Apr; 5(4):371-7. PubMed ID: 9759155
[TBL] [Abstract][Full Text] [Related]
42. Correlation between HRCT and pulmonary functional tests in cystic fibrosis.
Mastellari P; Biggi S; Lombardi A; Zompatori M; Grzincich G; Pisi G; Spaggiari C
Radiol Med; 2005 Oct; 110(4):325-33. PubMed ID: 16292239
[TBL] [Abstract][Full Text] [Related]
43. Effect of a short course of rhDNase on cough and mucociliary clearance in patients with cystic fibrosis.
Robinson M; Hemming AL; Moriarty C; Eberl S; Bye PT
Pediatr Pulmonol; 2000 Jul; 30(1):16-24. PubMed ID: 10862158
[TBL] [Abstract][Full Text] [Related]
44. Medium term treatment of stable stage cystic fibrosis with recombinant human DNase I.
Shah PL; Scott SF; Fuchs HJ; Geddes DM; Hodson ME
Thorax; 1995 Apr; 50(4):333-8. PubMed ID: 7785003
[TBL] [Abstract][Full Text] [Related]
45. High-resolution CT scanning: potential outcome measure.
Robinson TE
Curr Opin Pulm Med; 2004 Nov; 10(6):537-41. PubMed ID: 15510063
[TBL] [Abstract][Full Text] [Related]
46. Aerosolized recombinant human DNase I for the treatment of cystic fibrosis.
Shak S
Chest; 1995 Feb; 107(2 Suppl):65S-70S. PubMed ID: 7842816
[TBL] [Abstract][Full Text] [Related]
47. Airway inflammation after treatment with aerosolized deoxyribonuclease in cystic fibrosis.
Henry RL; Gibson PG; Carty K; Cai Y; Francis JL
Pediatr Pulmonol; 1998 Aug; 26(2):97-100. PubMed ID: 9727759
[TBL] [Abstract][Full Text] [Related]
48. Changes in structural lung disease in cystic fibrosis children over 4 years as evaluated by high-resolution computed tomography.
Carpio C; Albi G; Rayón-Aledo JC; Álvarez-Sala R; Girón R; Prados C; Caballero P
Eur Radiol; 2015 Dec; 25(12):3577-85. PubMed ID: 25929944
[TBL] [Abstract][Full Text] [Related]
49. Comparison of hypertonic saline and alternate-day or daily recombinant human deoxyribonuclease in children with cystic fibrosis: a randomised trial.
Suri R; Metcalfe C; Lees B; Grieve R; Flather M; Normand C; Thompson S; Bush A; Wallis C
Lancet; 2001 Oct; 358(9290):1316-21. PubMed ID: 11684212
[TBL] [Abstract][Full Text] [Related]
50. RhDNase I aerosol deposition and related factors in cystic fibrosis.
Diot P; Palmer LB; Smaldone A; DeCelie-Germana J; Grimson R; Smaldone GC
Am J Respir Crit Care Med; 1997 Nov; 156(5):1662-8. PubMed ID: 9372691
[TBL] [Abstract][Full Text] [Related]
51. Multicenter, open-label study of recombinant human DNase in cystic fibrosis patients with moderate lung disease. DNase International Study Group.
Harms HK; Matouk E; Tournier G; von der Hardt H; Weller PH; Romano L; Heijerman HG; FitzGerald MX; Richard D; Strandvik B; Kolbe J; Kraemer R; Michalsen H
Pediatr Pulmonol; 1998 Sep; 26(3):155-61. PubMed ID: 9773909
[TBL] [Abstract][Full Text] [Related]
52. Cystic fibrosis: when should high-resolution computed tomography of the chest Be obtained?
Santamaria F; Grillo G; Guidi G; Rotondo A; Raia V; de Ritis G; Sarnelli P; Caterino M; Greco L
Pediatrics; 1998 May; 101(5):908-13. PubMed ID: 9565424
[TBL] [Abstract][Full Text] [Related]
53. A six-month study of growth and energy expenditure in children with cystic fibrosis taking a pulmonary inhalation medication (rhDNase).
Fung EB; Barden EM; Wasserman D; Zemel BS; Heinrich BT; Scanlin TF; Stallings VA
J Am Coll Nutr; 1999 Aug; 18(4):330-8. PubMed ID: 12038476
[TBL] [Abstract][Full Text] [Related]
54. Early smoking-induced lung lesions in asymptomatic subjects. Correlations between high resolution dynamic CT and pulmonary function testing.
Spaggiari E; Zompatori M; Verduri A; Chetta A; Bnà C; Ormitti F; Sverzellati N; Rabaiotti E
Radiol Med; 2005; 109(1-2):27-39. PubMed ID: 15729184
[TBL] [Abstract][Full Text] [Related]
55. Dornase alfa in early cystic fibrosis lung disease.
Robinson PJ
Pediatr Pulmonol; 2002 Sep; 34(3):237-41. PubMed ID: 12203856
[TBL] [Abstract][Full Text] [Related]
56. Computed tomography correlates with pulmonary exacerbations in children with cystic fibrosis.
Brody AS; Sucharew H; Campbell JD; Millard SP; Molina PL; Klein JS; Quan J
Am J Respir Crit Care Med; 2005 Nov; 172(9):1128-32. PubMed ID: 16100015
[TBL] [Abstract][Full Text] [Related]
57. Effect of treatment with dornase alpha on airway inflammation in patients with cystic fibrosis.
Paul K; Rietschel E; Ballmann M; Griese M; Worlitzsch D; Shute J; Chen C; Schink T; Döring G; van Koningsbruggen S; Wahn U; Ratjen F;
Am J Respir Crit Care Med; 2004 Mar; 169(6):719-25. PubMed ID: 14684561
[TBL] [Abstract][Full Text] [Related]
58. The use of human deoxyribonuclease (rhDNase) in the management of cystic fibrosis.
Suri R
BioDrugs; 2005; 19(3):135-44. PubMed ID: 15984899
[TBL] [Abstract][Full Text] [Related]
59. Sinonasal inhalation of dornase alfa administered by vibrating aerosol to cystic fibrosis patients: a double-blind placebo-controlled cross-over trial.
Mainz JG; Schien C; Schiller I; Schädlich K; Koitschev A; Koitschev C; Riethmüller J; Graepler-Mainka U; Wiedemann B; Beck JF
J Cyst Fibros; 2014 Jul; 13(4):461-70. PubMed ID: 24594542
[TBL] [Abstract][Full Text] [Related]
60. Automated CT scan scores of bronchiectasis and air trapping in cystic fibrosis.
DeBoer EM; Swiercz W; Heltshe SL; Anthony MM; Szefler P; Klein R; Strain J; Brody AS; Sagel SD
Chest; 2014 Mar; 145(3):593-603. PubMed ID: 24114359
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
